Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656839 | 0.83 | GCK (0.55) | GCKKCNH2 | |
| SCHEMBL2657403 | 0.82 | GCK (0.40) | GCKKCNH2 | |
| SCHEMBL2658151 | 0.80 | GCK (0.52) | GCKKCNH2 | |
| SCHEMBL2659314 | 0.79 | GCK (0.55) | GCKKCNH2 | |
| SCHEMBL2657535 | 0.78 | GCK (0.48) | GCKKCNH2 | |
| SCHEMBL2658076 | 0.75 | GCK (0.56) | GCKKCNH2 | |
| SCHEMBL2073309 | 0.75 | GCK (0.56) | GCKKCNH2 | |
| SCHEMBL2656565 | 0.72 | GCK (0.64) | GCKKCNH2 | |
| SCHEMBL12021269 | 0.69 | GCK (0.70) | GCKKCNH2 | |
| SCHEMBL2652474 | 0.69 | GCK (0.73) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086964-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | Astra Zeneca AB (SE) | 2009-08-12 | — | — | EP | claimed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | claimed |
| EP-2086964-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | Astra Zeneca AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |